![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZMYM6 |
Gene summary for ZMYM6 |
![]() |
Gene information | Species | Human | Gene symbol | ZMYM6 | Gene ID | 9204 |
Gene name | zinc finger MYM-type containing 6 | |
Gene Alias | Buster2 | |
Cytomap | 1p34.3 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O95789 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9204 | ZMYM6 | HCC1_Meng | Human | Liver | HCC | 2.26e-25 | 5.01e-02 | 0.0246 |
9204 | ZMYM6 | HCC2_Meng | Human | Liver | HCC | 4.69e-15 | 6.88e-02 | 0.0107 |
9204 | ZMYM6 | HCC1 | Human | Liver | HCC | 2.36e-04 | 2.56e+00 | 0.5336 |
9204 | ZMYM6 | HCC2 | Human | Liver | HCC | 2.26e-13 | 2.98e+00 | 0.5341 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002260422 | Liver | HCC | regulation of cell morphogenesis | 188/7958 | 309/18723 | 4.84e-11 | 1.82e-09 | 188 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZMYM6 | SNV | Missense_Mutation | novel | c.2286N>A | p.Ser762Arg | p.S762R | O95789 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.505) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ZMYM6 | SNV | Missense_Mutation | rs759201841 | c.784N>A | p.Ala262Thr | p.A262T | O95789 | protein_coding | tolerated(0.23) | benign(0.119) | TCGA-D1-A17M-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZMYM6 | SNV | Missense_Mutation | c.2018A>G | p.Lys673Arg | p.K673R | O95789 | protein_coding | tolerated(0.47) | benign(0.013) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZMYM6 | SNV | Missense_Mutation | novel | c.490N>T | p.Asp164Tyr | p.D164Y | O95789 | protein_coding | deleterious(0.01) | probably_damaging(0.974) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ZMYM6 | SNV | Missense_Mutation | c.608N>A | p.Arg203Gln | p.R203Q | O95789 | protein_coding | tolerated(0.54) | benign(0.275) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZMYM6 | SNV | Missense_Mutation | rs201643072 | c.464N>A | p.Arg155His | p.R155H | O95789 | protein_coding | deleterious(0.04) | possibly_damaging(0.553) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZMYM6 | SNV | Missense_Mutation | novel | c.3332N>T | p.Gly1111Val | p.G1111V | O95789 | protein_coding | deleterious(0.02) | benign(0) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZMYM6 | SNV | Missense_Mutation | rs781499641 | c.2450N>A | p.Ser817Tyr | p.S817Y | O95789 | protein_coding | deleterious(0.05) | benign(0) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZMYM6 | SNV | Missense_Mutation | rs761036576 | c.3480G>T | p.Glu1160Asp | p.E1160D | O95789 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.681) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ZMYM6 | SNV | Missense_Mutation | novel | c.1823C>A | p.Ser608Tyr | p.S608Y | O95789 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |